Kura and Profound Signal Commercial Inflection Points in Q4 Results

The fourth-quarter earnings reports from Kura Oncology and Profound Medical underscore a broader trend in the mid-cap healthcare sector: the transition from clinical validation to commercial scalability. Both companies, though operating in different niches—oncology therapeutics and medical devices—delivered updates on March 5, 2026, that suggest 2026 will be a defining year for their respective market valuations. For Kura Oncology, the focus remains squarely on ziftomenib, its potent and selective menin inhibitor. For Profound Medical, the narrative has shifted from 'if' clinicians will adopt its TULSA-PRO system to 'how fast' they can scale under a newly established reimbursement framework.

Kura Oncology’s financial results reflect the heavy investment required to bring a precision oncology drug to the finish line. The company reported a net loss for the quarter, consistent with its status as a pre-revenue biotech, but its cash runway remains a primary strength. With over $450 million in cash and short-term investments, Kura is well-capitalized to fund operations through the anticipated launch of ziftomenib in 2027. The clinical data from the KOMET-001 trial continues to show a best-in-class profile for ziftomenib in patients with NPM1-mutant acute myeloid leukemia (AML). Management indicated that they are in active dialogue with the FDA regarding a New Drug Application (NDA) submission, which could occur as early as mid-2026. This puts Kura in direct competition with Syndax Pharmaceuticals, though Kura’s management emphasized ziftomenib’s safety profile, particularly the low incidence of differentiation syndrome, as a key differentiator.

“

With over $450 million in cash and short-term investments, Kura is well-capitalized to fund operations through the anticipated launch of ziftomenib in 2027.

Profound Medical, conversely, is already in the commercial phase and is finally seeing the fruits of a multi-year regulatory and reimbursement battle. The company reported record quarterly revenue, driven by a significant uptick in TULSA-PRO procedure volumes. This growth is directly attributable to the January 2025 implementation of Category 1 CPT codes, which simplified the billing process for hospitals and urology clinics. During the earnings call, management noted that the 'reimbursement hurdle' has largely been cleared, and the focus has now shifted to expanding the installed base of systems. Profound’s 'razor-and-blade' model—where they earn recurring revenue from disposables used in each procedure—is beginning to show the operating leverage that investors have long anticipated. The company’s gross margins improved sequentially, reflecting higher utilization rates across its U.S. partner sites.